1. Home
  2. RNTX vs CMTL Comparison

RNTX vs CMTL Comparison

Compare RNTX & CMTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.78

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Logo Comtech Telecommunications Corp.

CMTL

Comtech Telecommunications Corp.

HOLD

Current Price

$1.75

Market Cap

52.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNTX
CMTL
Founded
2001
1967
Country
United States
United States
Employees
N/A
1385
Industry
Biotechnology: Pharmaceutical Preparations
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
65.3M
52.7M
IPO Year
2017
2024

Fundamental Metrics

Financial Performance
Metric
RNTX
CMTL
Price
$0.78
$1.75
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$10.00
$6.00
AVG Volume (30 Days)
427.7K
306.0K
Earning Date
05-15-2026
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
44.16
N/A
EPS
N/A
N/A
Revenue
N/A
$499,528,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$4.56
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$1.59
52 Week High
$2.18
$6.21

Technical Indicators

Market Signals
Indicator
RNTX
CMTL
Relative Strength Index (RSI) 44.63 46.98
Support Level $0.69 $1.64
Resistance Level $0.88 $1.86
Average True Range (ATR) 0.06 0.08
MACD 0.01 0.04
Stochastic Oscillator 19.75 81.08

Price Performance

Historical Comparison
RNTX
CMTL

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About CMTL Comtech Telecommunications Corp.

Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.

Share on Social Networks: